Travere Therapeutics, Inc. (TVTX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-591.5%

-$242.11

vs $49.26 price

Levered DCF

-$314.54

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

1.52

Distress zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-68.23×	-4.27×	-5.99×	-4.81×	-10.31×	-7.66×	-4.1×	-8.91×
P/B	29.69×	23.26×	3.32×	31.29×	6.15×	6.13×	2.72×	2.87×
P/S	6.95×	5.89×	4.6×	12.25×	14.09×	6.53×	3.43×	5.57×
EV / EBITDA	164.03×	-6.46×	-3.11×	-5.63×	-10.59×	-10.02×	-7.03×	-14.03×
Gross margin	97.9%	96.7%	92.1%	96.0%	97.1%	96.9%	97.0%	96.6%
Operating margin	-12.8%	-138.9%	-267.2%	-292.2%	-151.3%	-88.8%	-56.9%	-48.7%
Net margin	-5.2%	-137.9%	-76.7%	-254.4%	-136.6%	-85.4%	-83.5%	-62.5%
Current ratio	2.74×	2.08×	3.47×	3.42×	4.7×	4.43×	4.5×	4.74×
Debt / equity	2.86×	6.8×	2.02×	9.51×	0.87×	1.16×	0.97×	0.68×
Interest coverage	-5.85×	-28.96×	-34.25×	-29.04×	-10.13×	-9.25×	-5.3×	-8.16×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-22.2%	-544.3%	-55.5%	-649.9%	-59.6%	-80.2%	-66.2%	-32.3%
Return on invested capital	-13.9%	-69.3%	-63.0%	-59.8%	-30.4%	-30.7%	-19.5%	-12.8%
Return on assets	-4.2%	-54.1%	-14.1%	-41.4%	-23.2%	-27.9%	-24.2%	-14.5%
Free cash flow yield	-0.6%	-24.6%	-48.2%	-16.0%	-2.1%	-12.5%	-12.3%	-4.9%
Earnings yield	-0.7%	-23.4%	-16.7%	-20.8%	-9.7%	-13.1%	-24.4%	-11.2%
Enterprise value	$3.6B	$1.7B	$1B	$1.7B	$2B	$1.5B	$753.7M	$1B
Net debt / EBITDA	10.61×	-1.29×	-1.06×	-1.15×	-0.52×	-1.1×	-1.42×	-1.56×
Cash conversion cycle (days)	-609	-775	-975	-999	-705	-209	-1,394	-56